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Introduction: Human parthenogenetic embryonic stem cells (hpESCs) are generated from artificially activated
oocytes, however, the issue of whether hpESCs have equivalent differentiation ability to human fertilized embryonic
stem cells remains controversial.
Methods: hpESCs were injected into male severe combined immunodeficiency (SCID) mice and the efficiency of
teratoma formation was calculated. Then the gene expression and methylation modification were detected by real
time-PCR and bisulfate methods.
Results: Comparison of five hpESCs with different differentiation abilities revealed that levels of paternal genes in
the Dlk1-Dio3 region on chromosome 14 in the hpESCs with high differentiation potential are enhanced, but strictly
methylated and silenced in the hpESCs with lower differentiation potential. Treatment with ascorbic acid, rescued
their ability to support teratoma formation and altered the expression profiles of paternally expressed genes in
hpESCs that could not form teratoma easily. No differences in the expression of other imprinting genes were evident
between hpESCs with higher and lower differentiation potential, except for those in the Dlk1-Dio3 region.
Conclusions: The Dlk1-Dio3 imprinting gene cluster distinguishes the differentiation ability of hpESCs. Moreover,
modification by ascorbic acid may facilitate application of hpESCs to clinical settings in the future by enhancing their
pluripotency.Introduction
Human embryonic stem cells (hESCs) have tremendous
potential in regenerative medicine and cell therapy, as
they can differentiate into cell derivatives of all three pri-
mary germ layers, endoderm, mesoderm and ectoderm.
To obtain clinically applicable hESCs, parthenogenetic
activation methods are preferred to the conventional
method requiring oocyte fertilization. However, applica-
tion of established cloned hESCs to the clinic is difficult
at present because the hemagglutinating virus of Japan is* Correspondence: fanyong0413@sina.com; jie.qiao@263.net
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unless otherwise stated.used in all successful cases [1,2], whereas the hemagglu-
tinating virus of Japan is not allowed to be used in the
clinic at present. Therefore, parthenogenetic ES cells
(pESCs) that were from parthenogenetic activated oocytes
using an artificial method permitted in clinic settings [3],
may be more feasible for clinical application.
pECSs have been derived from mouse [4], rabbit [5],
monkey [6] and human sources [7-10], and their ability
to differentiate into neurons and endoderm cells has
been widely confirmed. Imbalance of imprinting gene
expression and unique epigenetic modifications in the
whole genome is reported to impair the pluripotency of
pESCs. Allen and co-workers reported varying differenti-
ation abilities of mouse pESCs, with some contributing
to generation of mice after injection into tetraploidis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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particularly for skeletal muscle [11]. Vassena et al. sug-
gested that loss of differentiation ability is easier during
serial differentiation and reprogramming processes for
human pESCs (hpESCs) [12]. Furthermore, in a study by
Mai and co-workers, one of the hpESC lines failed to
form derivatives from three germ layers, consistent with
the suggestions of Lu et al. [13] and Liu et al. [14].
Clearly, defects in differentiation ability of hpESCs limit
their clinical application.
The Dlk1-Dio3 genomic regions were evolutionarily
conserved in mammals. This region includes the pater-
nally expressed genes Dlk1, Rtl1, and Dio3, and mater-
nally expressed genes Meg3, Meg8, and antisense Rtl1.
In mouse, aberrant silencing of the imprinted Dlk1-Dio3
gene cluster was observed in most induced pluripotent
stem cell (iPSC) clones that contributed poorly to
chimeras and failed to support the development of
iPSC-derived animals [15,16]. Subsequently, Stadtfeld et al.
demonstrated that ascorbic acid attenuates hypermethyla-
tion of the Dlk1-Dio3 cluster, consequently enhancing the
pluripotency of iPSCs reprogrammed from differentiated B
cells [17]. Further studies by Bryce et al. suggested that ab-
errant DNA methylation within the Dlk1-Dio3 locus de-
creases the efficiency of generating mice via tetraploid
complementation, supporting the contribution of this locus
to the formation of low-quality iPSCs [18]. In addition to
iPSCs, activation of paternally expressed imprinted genes
in mouse pESCs enhances their pluripotency, even result-
ing in the production of germline-competent mice [19].
Additionally, expression profiling of the Dlk1-Dio3 cluster
is correlated with pluripotency of iPSCs in pigs [20].
While studies on the Dlk1-Dio3 imprinting domain in
hESCs have mainly focused on the field of tumor pro-
motion, limited reports to date have validated the signifi-
cance of this domain gene locus. Xie et al. showed that
silencing of the Dlk1-Dio3 cluster of hESCs impairs
generation of their differentiated hepatocyte-like cell
derivatives but does not compromise multilineage dif-
ferentiation ability [21]. Furthermore, the group of Sun
revealed that the conserved miRNA cluster within the
imprinted Dlk1-Dio3 region is highly expressed in
mouse and rhesus macaque ESCs but rarely in hESCs
[22]. Therefore, determination of expression patterns of
the Dlk1-Dio3 cluster in hpESCs and analysis of its role
in pluripotency regulation of hpESCs is necessary.
In the present study, we found that the Dlk1-Dio3
gene locus in hpESCs is aberrantly expressed and meth-
ylated, which correlated with teratoma formation. Fur-
thermore, we examined the effects of ascorbic acid on
methylation and gene expression patterns in the Dlk1-
Dio3 cluster, with a view to ascertaining whether this
compound contributes to improvement of the differenti-
ation ability of hpESCs.Methods
Ethical approval
The current study was approved by the Institutional
Review Board of Peking University Third Hospital and
Guangzhou Medical University Affiliated Third Hospital.
The volunteers involved in the present study were in-
formed of all details of the procedure, including sample
utility and research destination, and voluntarily signed
an informed consent document. All necessary consents
from any participatant involved in the study, including
consent to participate in the study, were obtained.Construction and culture of human fertilized and
parthenogenetic embryos
Immature oocytes were collected from patients in the
ICSI cycle because of male factor infertility in the repro-
ductive medical centers at both Peking University Third
Hospital and Guangzhou Medical University Affiliated
Third Hospital. All immature oocytes were cultured in
commercial in vitro maturation medium (SAGE In Vitro
Fertilization, Inc., San Clemente, California, U.S.), and
those that expelled the first polar body were regarded as
mature oocytes at the metaphase II stage. One portion
of MII oocytes was subjected to intra-cytoplasmic sperm
injection (ICSI) micromanipulation to construct fertilized
embryos and the other portion artificially activated by treat-
ment for five minutes with 5 μM ionomycin and for two
hours with 2 mM 6- dimethylaminopyridine (6-DMAP) to
form parthenogenetic embryos. All embryos were cultured
in G-1 medium, followed by G-2 medium from the eight-
cell to the blastocyst stages (G1 and G2 medium were all
purchased from Vitrolife Inc., Goteborg, Sweden).Derivation of hESCs from fertilized and parthenogenetic
activated embryos
Expanded blastocysts were removed of zona pellucida
using Tyrode’s solution, and the inner cell mass isolated
via immunosurgery and placed on mitomycin C-treated
murine embryonic fibroblast (MEF) feeder layers. After
7 to 10 days, the primary colony was transferred to a
new feeder layer and culture continued for 10 more
days. The ESC colony was dissected into four to eight
pieces upon passage and implanted into new feeder
layers. Two hpESCs and three human fertilized embry-
onic stem cell (hfESCs) lines were derived sucessfully.
The former was designated as BGHPES-1 and BGHPES-2,
and the latter was designated as BGHFESC-1, BGHFES-2
and BGHFES-3, which were also named FHES-CONT.General characterization of human embryonic stem cells
Characteristics of hESCs were determined using estab-
lished protocols [23], as follows:
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AP activity was assessed in both hfESCs and hpESCs.
Cell colonies were stained with BCIP/NBT for 8 to 12
minutes and examined under an inverted microscope.
Immunofluorescence staining
hESC colonies were removed to a glass sheet and fixed
using 4% paraformaldehyde for 30 minutes. Fixed ESC
colonies were permeabilized with 0.2% Triton X-100 for
30 minutes, followed by blocking in 3% BSA in PBS
for 2 hours. Subsequently, colonies were incubated with
1:100 diluted primary antibodies, those specific for stem
cell pluripotent markers (OCT4 and NANOG) (OCT4:
1:200, ab27985, Abcam, Cambridge, UK; NANOG:
ab80892, Abcam) and stem cell surface markers (TRA-
1-60) (1:200, ab16288, Abcam), and stained with the cor-
responding secondary antibodies, followed by treatment
with 10 μg/mL propidium iodide for 30 minutes. Fluor-
escence was assessed under a confocal microscope
(A1R, Nikon Corp., Tokyo, Japan).
Karyotyping
hESC colonies were implanted onto matrigel without a
feeder layer, and cells collected after three-days culture.
Next, colonies were rinsed in PBS solution and incu-
bated in 0.075 mol/L potassium chloride for 10 minutes
at 37°C. Finally, cells were fixed with methanol/glacial
acetic acid and dropped onto glass slides. Chromosome
spreads were Giemsa-banded and photographed. The
karyotypes of hESCs were determined every 10 passages.
Differentiation in vitro and in vivo
hESCs were differentiated into embryoid bodies (EBs)
in vitro by suspension culture. After 10 to 14 days, EBs
were collected, and gene expression analyzed using RT-
PCR methods. Specific genes in all three embryonic germ
layers, including AFP (endoderm) (1:100, Human Germ
Layer Marker Kit, Chemicon, Merck Millipore Corporation.
The United States, Massachusetts city), SMA(mesoderm)
(1:200, Human Germ Layer Marker Kit, Chemicon) and
TUBULIN (ectoderm) (1:200, Human Germ Layer Marker
Kit, Chemicon), were identified using immunofluorescence,
and Nf68kd (endoderm), Hbz (mesoderm) and Albumin
(ectoderm) with RT-PCR. Gene primers are listed in
Additional file 1.
For in vivo differentiation, hESCs were injected into
the inguinal grooves of six-week-old male severe com-
bined immunodeficiency (SCID) mice after division into
300 to 400 small colonies. After two months, tumors
were examined. All tumors were fixed for four to eight
hours in 4% paraformaldehyde and embedded in paraf-
fin. Sections were subsequently stained with hematoxylin
and eosin, and examined under a light microscope for
the presence of tissue derived from the three germlayers. In cases where tumors did not form within the
two-month period, an equivalent volume of hESC colonies
was injected into the same location. After three repeats of
this step, hESCs were considered non-pluripotent.
Gene expression profile analysis
Total RNA was extracted and purified using TRIzol with
an established kit, and cDNA was generated from extracted
RNA using reverse transcription. PCR was carried out
using primers for the paternally expressed genes, Dlk1,
Rtl1, and Dio3, and the maternally expressed genes, Meg3,
Meg8, and antisense Rtl1 encoding miR433 and miR127.
Amplified products were analyzed on a 1.5% agarose gel,
visualized via ethidium bromide (Invitrogen, Life Technolo-
gies Corporation., Carlsbad, Calfornia, US) staining, and
imaged using the BioImaging system (UVP, Upland, CA,
USA). Ubiquitously expressed glyceraldehyde-3-phosphate
dehydrogenase (Gapdh) was used as a control. Quantitative
real-time PCR for the tested genes was performed on an
ABI 7500 (Applied Biosystems, Life Technologies Corpor-
ation., Foster, Calfornia, US) system using the TaqMan real-
time PCR probe primer mixture according to a previous
study by Kagami et al. [24].
DNA methylation analysis via bisulfite modification
Genomic DNA was extracted via proteinase K digestion
and phenol/chloroform extraction [25], denatured with
NaOH and modified using sodium bisulfite and hydro-
quinone. Bisulfite-treated DNA was purified using a
Wizard DNA clean-up system (Promega, Madison, WI,
USA), following the manufacturer’s instructions. DNA
was precipitated with ethanol after treatment with
NaOH and eluted into 50 μl distilled water. The final
products were stored at −80°C until use.
Bisulfite treatment was performed using an EpiTect
Bisulfite Kit (Qiagen, Hilden, Germany) according to
the manufacturer’s manual. Bisulfite-converted DNA was
amplified using nested PCR. Primer sequences are shown
in Additional file 1. Each 25 μl PCR reaction mixture
contained 4 μl of bisulfite-treated DNA, and reactions
were performed according to the method described by
Kagamiet al. [26,27]. The presence of amplified products
was confirmed by electrophoresis on a 1.5% agarose gel.
PCR products were retrieved and ligated into the
pMD19-T Vector System (TaKaRa). After transformation
via heat shock into 200 μl competent Top10 cells (Tiangen,
Beijing, China), colonies were isolated and cultured. For
each sample, 15 positive clones were sequenced.
Ascorbic acid supplementation during hESC culture
hpESCs were cultured in knockout (D)MEM medium
supplemented with 20% KnockOut Serum Replace-
ment (Gibco, Life Technologies Corporation., Carlsbad,
Calfornia, US), 1 mM glutamine (Sigma, Sigma, St . Louis,
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mM 2-mercaptoethanol (Sigma), 50 UI/ml penicillin
(Sigma), and 50 UI/ml streptomycin (Sigma) mixture. At
passage 21, 100 μg/ml ascorbic acid were added to the
ESC culture medium until the end of the experiment.
hpESCs cultured without ascorbic acid were taken as the
control group.
Statistical analysis
Data were analyzed using SPSS 17.0 software. The differ-
ences between the two groups were calculated with the
chi-square test, and those among multiple groups with
one-way analysis of variance (ANOVA). Data were con-
sidered significantly different at P values less than 0.05.
Results
Derivation and identification of hpESCs
In total, 106 mature oocytes at the MII stage were obtained
from 163 immature oocytes (112 GV and 51 MI oocytes).
Among these, 82 oocytes were successfully activated, from
which six blastocysts were developed. Four of the six blas-
tocysts displayed regular morphology, including trophecto-
derm cells with a willow leaf shape and compacted inner
cell mass. Three primary colonies formed and grew after
five days, two of which were propagated until the present
time (designated BGHPES-1 and BGHPES-2). Representa-
tive oocyte or embryo morphologies and derivation effi-
ciencies are shown in Figure 1.
The two hpESCs lines were propagated every four to
seven days, and colonies displayed typical hESC morph-
ology, including higher nuclear/cytoplasm ratio and com-
pacted cell conjunction. BGHPES-1 and -2 lines wereFigure 1 Development of human parthenogenetic embryonic stem cells. (
with two pronuclei; (D) two-cell embryo; (E) eight-cell embryo; (F) Blastocyst;
embryonic stem cells. Bar is 50 μm.positive for AP activity and pluripotent markers, including
OCT-4 and NANOG, as well as the cell surface marker,
TRA-1-60. Moreover, these ESCs displayed the normal
chromosome karyotype, 46 XX (Figure 2). Upon differen-
tiation in vitro, both ESC lines contributed to derivatives
from all three germ layers, as confirmed by both immuno-
fluorescence staining and RT-PCR (Figure 3A-C and D).
Following injection into SCID mice, teratomas formed
and grew (Figure 3E). However, the differentiation abilities
of the two ESC lines were variable. For BGHPES-1, tera-
toma was observed in nine out of ten non-SCID mice, and
derivatives from all three germ layers were identified. In
contrast, for BGHPES-2, two teratomas were observed
among ten non-SCID mice, but only one contained deriv-
atives from all three germ layers and the other contained
derivatives from ectoderm and mesoderm layers only.
HFES-CONT lines contributed to teratoma formation
with 100% efficiency (Figure 3F).
Gene expression and methylation modifications in the
Dlk1-Dio3 region
Imprinted gene expression profiles in the Dlk1-Dio3 re-
gion were determined, including those of paternally
expressed genes, Dlk1, Rtl1 and Dio3, and maternally
expressed genes, Meg3, Meg8 and antisense Rtl1 (encod-
ing miR433 and miR127). The results appeared consistent
with methylation modification data. Decreasing expression
of paternal genes was observed, compared with the
HFESC-CONT line. However, paternally expressed genes
in BGHPES-1 were up-regulated, compared with those
of BGHPES-2 (Figure 4A). With regard to maternally
expressed genes, two- to four-fold enhanced expressionA) Immature oocytes; (B) Mature metaphase II oocytes; (C) Zygote
(G) Development from immature oocytes to human parthenogenetic
Figure 2 Identification of human parthenogenetic embryonic stem cells. (A) Colony of human parthenogenetic embryonic stem cells; (B) positive
staining for alkaline phosphatase; (C) normal 46, XX karyotype at passage 20; (D) positive staining for OCT4; (E) positive staining for NANOG; (F)
positive staining for TRA-1-60; (D1-F1) nuclear staining with Hoechst 33342; (D2-F2) merged images for OCT4, NANOG and TRA-1-60. Bar is 100 μm.
Figure 3 Differentiation abilities of human parthenogenetic embryonic stem cells. In vitro differentiated EBs displayed (A) positive AFP staining
(endoderm), (B) positive SMA staining (mesoderm), (C) positive TUBULIN staining (ectoderm), and (D) expression of genes from endoderm (NF68KD),
mesoderm (HBZ) and ectoderm (Albumin). Bar is 50 μm. (E) Efficiency of teratoma formation upon injection of human parthenogenetic embryonic
stem cells into SCID mice; (F) neuro-ectoderm from ectoderm in teratoma; (G) cartilage from mesoderm in teratoma; (H) glandular tissue from
endoderm in teratoma. Bar is 100 μm. EB, embryoid bodies; SCID, severe combined immunodeficiency.
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Figure 4 Relative mRNA expression of parental genes in the Dlk1-Dio3 region. (A) Expression of paternal genes was significantly higher in human
fertilized embryonic stem cells. Dlk1-Dio3 genes in BGHPES-1 were expressed at significantly higher levels, compared to BGHPES-2. (B) Maternally
expressed genes were significantly up-regulated with no significant differences in both BGHPES-1 and -2, compared with human fertilized embryonic
stem cells. Different letters indicate significant differences among data (P <0.05) while the same letters imply no differences (P >0.05).
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normal control. No differences in expression patterns of
maternal genes were evident between the two hpESC
lines, distinct from data obtained for paternally expressed
genes (Figure 4B).
Germline-derived primary Dlk1-Meg3 intergenic differ-
entially methylated region (IG-DMR) and postfertilization-
derived secondary Meg3-DMR were further analyzed. Both
DMRs were hypermethylated after paternal transmission
and hypomethylated after maternal transmission in the
body (Figure 5A). Our results disclosed methylation
modifications in approximately 2% of DMRs in BGHPES-
1 and -2 (Figure 5B and C). In the HFES-CONT line, half
of these regions were methylated, indicating balanced ex-
pression of imprinted genes in this cluster (Figure 5D).
To confirm these findings, we ascertained whether the
other three hpESCs have been established in Guangzhou
before, named GHPES-1, -2 and -3. Among the three
hpESC lines, GHPES-1 and -2 contributed to derivatives
from all three germ layers in teratoma with high frequency
(10/12 and 9/12, respectively), while GHPES-3 failed to
form teratoma, even after ESC injection more than ten
times (1/12) [See Additional file 2]. Gene expression
profiling revealed a significant increase in the levels of
paternally expressed genes in GHPES-1 and -2, compared
with GHPES-3 [See Additional file 2]. In contrast, no
differences were observed in the expression profiles of
maternally expressed genes [See Additional file 2]. The
proportion of DMR methylation modifications remained
at the 1% to 5% level, with no significant differences
among the three hpESC lines [See Additional file 3].
Ascorbic acid supplement alters the levels of paternally
expressed genes in the Dlk1-Dio3 region
To establish whether ascorbic acid (also known as Vc)
affects the pluripotency of hpESCs, culture media of the
five hpESC lines were supplemented with 100 μg/mlcompound. After propagating ESCs for 10 passages, rela-
tively higher expression of paternally imprinted genes
was detected at passages Vc + 3, Vc + 5 and Vc + 10 in
BGHPES-2 and GHPES-3 cell lines. In the BGHPES-2
line, paternal gene expression was increased at passage 5
after Vc treatment, while expression patterns of maternal
genes remained unchanged. Upon injection of hpESCs
into SCID mice, teratoma formation efficiency was sig-
nificantly increased with prolongation of Vc treatment
duration (Figure 6). Expression patterns of GHPES-3
genes displayed similar changes to those of BGHPES-2
(Figure 7). However, ascorbic acid supplementation did
not affect methylation of IG-DMR and MEG3-DMR in
both hpESC lines. In the three other hpESCs (BGHPES-
1, GHPES-1 and GHPES-2) and control hfESCs, gene
expression, teratoma formation and methylation modifi-
cation remained unaffected by ascorbic acid treatment
[See Additional files 4, 5, 6 and 7]. Moreover, we ob-
served that the expression level of Dlk1, Rtl1 and Dio3
in all five hpESCs was still significantly lower than con-
trol hfESCs, although Vc supplementation can enhance
these gene expression levels in BGHPES-2 and GHPES-
3 [See Additional file 8].
To confirm whether differences in paternally expressed
genes in Dlk1-Dio3 contribute to the in vivo differenti-
ation ability of hpESCs, expression profiles of 25 paternal
and 20 maternal genes were further examined. Gene
cluster data from paternally expressed genes indicated
a close correlation between BGHPES-2 and GHPES-3
that did not form teratomas easily and significantly lower
expression of Dlk1, Rtl1 and Dio3 in both lines. However,
after ascorbic acid treatment, this correlation between
BGHPES-2 and GHPES-3 cell lines was not evident, and
the characteristics of paternally expressed genes in the
Dlk1-Dio3 cluster normalized [See Additional file 9]. No
significant changes in the levels of maternally expressed
genes were observed [See Additional file 10].
Figure 5 Bisulfite sequencing analysis of IG-DMR (CG4 and CG6) and MEG3-DMR (CG7) using DNA samples from human parthenogenetic and
fertilized embryonic stem cells. (A) Schematics of IG-DMR and MEG3-DMR in Dlk1-Dio3 imprinting clusters. Normally, CG4 and CG6 structures from
IG-DMR and CG7 from MEG3-DMR were methylated (black dots) in paternally derived chromosomes, and unmethylated (white dots) in maternally
derived chromosomes; BGHPES-1 (B) and -2 (C) and control FHES-Cont (D) data. Each horizontal line indicates a single subcloned allele.
Hypomethylation was observed in BGHPES-1 and -2, and balanced methylation in control cells. IG-DMR, intergenic differentially methylated region.
Yu et al. Stem Cell Research & Therapy  (2015) 6:69 Page 7 of 12Discussion
Data from the present study suggest that the differences
in gene expression and methylation modifications in the
Dlk1-Dio3 region contribute to the differentiation ability
of hpESCs. Ascorbic acid supplementation narrows this
gap and enhances the ability of ESCs to form teratomas
in vivo by promoting paternal imprinted gene expression.
hpESCs are derived in multiple laboratories, and a
large proportion form teratomas after injection into
SCID mice, which appears similar to findings with
hfESCs [7-10]. However, two important facts should be
taken into consideration. One is that some established
hpESC lines fail to differentiate and form teratomas in
SCID mice, and the other is that no studies to date havefocused on the efficiency of teratoma formation for
pESCs. In the current study, efficiency of teratoma for-
mation was at least 70% in three of our hpESC lines, but
ranged from only 8.3% to 20% in the other two lines.
Based on the established criteria, these five hpESC lines
are categorized as normal ESCs. However, limited differ-
entiation ability restricts the potential clinical application
of some of these cells. The differentiation ability of
pESCs has been reported previously by Park and co-
workers, who showed that EBs differentiated from
mouse pESCs display growth retardation and only con-
tribute to derivatives of the endodermal layer [28].
Several methods have been developed to improve the
pluripotency of pESCs. Hikichi and co-workers established
Figure 6 Improvement in pluripotency of BGHPES-2 after treatment with ascorbic acid. (A) Procedure of ascorbic acid treatment. At passages 3, 5
and 10 after treatment with ascorbic acid, a portion of cells was collected for molecular testing and another portion injected into SCID mice to
form teratomas. (B) Paternally expressed genes were up-regulated in BGHPES-2 at passages 5 and 10. (C) No differences were observed for maternally
expressed genes in BGHPES-2 at passage 0, 3, 5 and 10. (D) Rate of teratoma formation was increased in BGHPES-2 at passage 5 and 10. No differences
in methylation modifications of IG-DMR and MEG3-DMR in BGHPES-2 were detected at passages 0 (E), 3 (F), 5 (G) and 10 (H). Different letters
indicate significant differences among data (P <0.05) while the same letters are used to signify no differences (P >0.05). IG-DMR intergenic
differentially methylated region; SCID, severe combined immunodeficiency.
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into oocytes and deriving these pESCs again at the blasto-
cyst stage (NT-pES), leading to two to five times enhance-
ment of differentiation ability, compared with the original
pESCs [29]. The same group reported development of
parthenogenetic embryos to term using the serial nuclear
transfer method [30]. Epigenetic modification was evi-
dently altered during reprogramming mediated by nuclear
transfer, and aberrant methylation observed in cloned em-
bryos and animals. In addition to the nuclear transfer
method, embryo aggregation at the eight-cell stage was
applied to improve imprinted gene expression in pESCs[31]. Turovets et al. treated hpESCs with trichostatin A, a
potent histone deacetylase inhibitor, facilitating differenti-
ation into the definitive endoderm lineage [32]. In the
present study, treatment of hpESCs with ascorbic acid
partly re-activated paternally imprinted gene expression
and, consequently, enhanced differentiation potential by
promoting teratoma formation.
Ascorbic acid is accepted as a beneficial agent for
somatic reprogramming into iPSCs, which acts biologic-
ally via Jhdm1a/Jhdm1b to enhance reprogramming
efficiency and maintain the imprinting status of the
Dlk1-Dio3 region to sustain reprogramming fidelity [33].
Figure 7 Improvement in pluripotency of GHPES-3 after ascorbic acid treatment. (A) Paternally expressed genes were up-regulated in GHPES-3 at
passage 5 and 10. (B) No differences were observed for maternally expressed genes in GHPES-3 at passages 0, 3, 5 and 10. (C) Rate of teratoma
formation was increased in GHPES-3 at passages 5 and 10. No differences in methylation modification of IG-DMR and MEG3-DMR in GHPES-3
were detected at passages 0 (D), 3 (E), 5 (F) and 10 (G). Different letters indicate significant differences among data (P <0.05) while the same
letters are used to signify no differences (P >0.05). IG-DMR intergenic differentially methylated region.
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transmission ability via teraploid complementation.
Stadtfeld et al. treated mouse iPSCs with ascorbic acid
at the primary reprogramming stage, and observed in-
creasing efficiency of mouse generation via teraploid
complementation [17]. The authors demonstrated that
ascorbic acid specifically attenuates hypermethylation of
maternal imprinting genes in Dlk1-Dio3 clusters, similar
to our results.
Dlk1-Dio3 is an evolutionarily conserved chromosome
region located in chromosome 12 in mice and chromo-
some 14 in humans [34]. Interestingly, Dlk1-Dio3 aber-
rations induce growth defects in both mice and humans
with similar phenotypes, indicating that the biological
function of Dlk1-Dio3 is analogous in these two species
[35-37]. The Dlk1-Dio3 region appears critical for the
pluripotency of iPSCs and tumor promotion [15,38,39].
Earlier data from two groups suggest that hypermethyla-
tion of maternally imprinted genes in Dlk1-Dio3 of
mouse iPSCs induces abnormal silencing of the locus
[17,40], in contrast to our finding that maternally
imprinted genes are overexpressed and paternally
imprinted genes are silenced in hpESCs. Another study
by Henzler and co-workers confirmed that overexpres-
sion of Dlk1-Dio3 miRNA early in reprogrammingreduces reprogramming efficiency [41], in accordance
with our findings. The results indicate that aberrant ex-
pression of imprinted genes in this region induces repro-
gramming deficiency, regardless of higher or lower
expression levels.
Re-activation of paternally expressed genes in the
Dlk1-Dio3 cluster appears beneficial for regaining pESC
pluripotency in mouse. Jiang et al. suggested that activa-
tion of paternally expressed imprinted genes in pESCs
induces germline transmission when injected into blas-
tocysts [19]. Another study by Li and co-workers indi-
cated that the culture environment in vitro induces
epigenetic changes in paternally expressed imprinted
genes, thereby increasing the pluripotency of pESCs [42].
We additionally observed differential expression of spe-
cific paternally expressed genes in established hpESCs.
However, normal expression of genes in the Dlk1-Dio3
cluster appears critical for pluripotency. Interestingly,
Dlk1, Rtl1 and Dio3 gene levels were enhanced upon
treatment of hpESCs with ascorbic acid, while IG-DMR
and MEG3-DMR methylation patterns remained un-
changed, indicating the involvement of other regulatory
mechanisms in this modification. Hiura and co-workers
demonstrated that valproic acid (VPA) enhances the
pluripotency of human iPSCs without methylation
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process may not be correlated with activation of pater-
nally expressed genes in the Dlk1-Dio3 region, support-
ing the contribution of other mechanisms in regulation
of expression.
Menzorov et al. found that mouse ESCs can contrib-
ute into teratoma and even in chimera although their
Dlk1-Dio3 imprinting control region is hypomethylated
[44]. This result is similar to our findings, which con-
firmed that poor methylation seems not to disturb ESCs
pluripotency, but in our results, important paternally
expressed genes in this imprinting region were up-
regulated and positively related to ESCs differentiation
ability, which indicated that methylation is not the only
regulation mode for these genes in the Dlk1-Dio3 re-
gion. Non-coding RNAs may be an undelying regulator
for the expression of these genes. In the Dlk1-Dio3
region, the maternally expressed genes can produce
non-coding RNAs, including mir-431, mir-433, mir-127,
mir-432 and mir-136. Liu et al. suggested that micro-
RNAs in the Dlk1-Dio3 region can potentially target
components of the polycomb repressive complex 2
(PRC2) and may form a feedback regulatory loop result-
ing in the expression of all genes and non-coding RNAs
encoded by this region [15]. Regarding the fact that
microRNA expression can be regulated by ascorbic acid
treatment [45], it is possible that ascorbic acid indirectly
changed the expression level of paternal genes by micro-
RNA regulation.
Imprinting genes have shown a tremendous potential
to regulate their pluripotency and multi-differentiation
ability. During cell differentiation and tissue formation,
it is critical that genomic demethylation and de novo
methylation take place for lineage specification and to
establish tissue-specific methylation patterns. Often,
non-fertilized-originated human pluripotent stem cells
showed abnormal epigenetic modification and imprint-
ing gene expression, including nuclear transfer embry-
onic stem cells [46] and iPSCs [47]; however, hpESCs
have a stable epigenetic modification mode, which is dif-
ferent from the dynamics and inconsistent epigenetic
status in the other two kinds of pluripotent stem cells.
In 2004, Kono et al. proved first that modification of
H19 and IGF2 in oocytes can result in the birth of par-
thenogenetic mice [48]. This indicated that H19-IGF2
was important to parthenogenesis, which suggested that
manipulation of imprinting genes can reverse parthenote
to fertilization-like status. In Mitalipov's study, he sug-
gested that hypermethylation within the IGF2/H19 IC in
all analyzed primate ESC lines resulted in a risk of cellu-
lar overproliferation and tumor formation [49]. Recently,
Yin et al. demonstrated that knockdown of H19 can
improve mouse pESC differentiation potential in the
lineages of ectoderm and mesoderm [50]. In furtherstudy, H19-Ifg2 and Dlk1-Dio3 imprinting region co-
modification may have the greatest impact on improve-
ment of the differentiation ability of pESCs.
Conclusions
In conclusion, the efficiency of teratoma formation by
hpESCs is improved with ascorbic acid treatment, lead-
ing to enhancement of potential differentiation ability.
Ascorbic acid has beneficial effects on general human
physiology and may, therefore, be safely used as a stimu-
latory drug to facilitate clinical application of hpESCs.
Additional files
Additional file 1: Table S1. Gene primer sequence for RT-PCR.
Additional file 2: Figure S1. Teratoma formation and relative mRNA
expression of parental genes in the Dlk1-Dio3 region in GHPES-1, -2 and -3
groups. (A) Rate of teratoma formation was decreased in GHPES-3; (B)
Expression of paternal genes was significantly higher in human fertilized
embryonic stem cells. Dlk1-Dio3 genes in GHPES-1 and -2 were expressed
at significantly higher levels, compared to GHPES-3; (C) Maternally expressed
genes were significantly up-regulated with no significant differences in
among GHPES-1, -2 and -3, compared with human fertilized embryonic
stem cells. Different letters indicate significant differences among data
(P <0.05) while the same letters imply no differences (P >0.05).
Additional file 3: Figure S2. Bisulfite sequencing analysis of IG-DMR
(CG4 and CG6) and MEG3-DMR (CG7) using DNA samples from human
parthenogenetic and fertilized embryonic stem cells. (A) GHPES-1, -2 and -3
data. Each horizontal line indicates a single subcloned allele. Hypomethylation
was observed in BGHPES-1, -2 and -3.
Additional file 4: Figure S3. Improvement in pluripotency of BGHPES-1
after treatment with ascorbic acid. (A) Paternally expressed genes were
not changed in BGHPES-1 at each passage. (B) No differences were
observed for maternally expressed genes in BGHPES-1 at passages 0, 3, 5
and 10. (C) Rate of teratoma formation was increased in BGHPES-1 at
passage 5 and 10; no differences in methylation modifications of IG-DMR
and MEG3-DMR in BGHPES-1 were detected at passages 0 (D), 3 (E), 5 (F)
and 10 (G). Different letters indicate significant differences among data
(P <0.05) while the same letters are used to signify no differences (P >0.05).
Additional file 5: Figure S4. Improvement in pluripotency of GHPES-1
after treatment with ascorbic acid. (A) Paternally expressed genes were
not changed in GHPES-1 at each passage. (B) No differences were observed
for maternally expressed genes in GHPES-1 at passages 0, 3, 5 and 10. (C)
Rate of teratoma formation was increased in GHPES-1 at passages 5 and 10;
no differences in methylation modifications of IG-DMR and MEG3-DMR in
GHPES-1 were detected at passages 0 (D), 3 (E), 5 (F) and 10 (G). Different
letters indicate significant differences among data (P <0.05) while the same
letters are used to signify no differences (P >0.05).
Additional file 6: Figure S5. Improvement in pluripotency of GHPES-2
after treatment with ascorbic acid. (A) Paternally expressed genes were
not changed in GHPES-2 at each passage. (B) No differences were observed
for maternally expressed genes in GHPES-2 at passages 0, 3, 5 and 10. (C)
Rate of teratoma formation was increased in GHPES-2 at passage 5 and 10;
no differences in methylation modifications of IG-DMR and MEG3-DMR in
GHPES-2 were detected at passages 0 (D), 3 (E), 5 (F) and 10 (G). Different
letters indicate significant differences among data (P <0.05) while the same
letters are used to signify no differences (P >0.05).
Additional file 7: Figure S6. Improvement in pluripotency of HFES-
CONT after treatment with ascorbic acid. (A) Paternally expressed genes
were not changed in HFES-CONT at each passage. (B) No differences
were observed for maternally expressed genes in HFES-CONT at passages
0, 3, 5 and 10. (C) Rate of teratoma formation was increased in HFES-
CONT at passage 5 and 10; no differences in methylation modifications
of IG-DMR and MEG3-DMR in HFES-CONT were detected at passages 0
Yu et al. Stem Cell Research & Therapy  (2015) 6:69 Page 11 of 12(D), 3 (E), 5 (F) and 10 (G). Different letters indicate significant differences
among data (P <0.05) while the same letters are used to signify no
differences (P >0.05).
Additional file 8: Figure S7. Dynamic changes of paternally expressed
genes in hpESCs after ascorbic acid treatment. In Vc + 0 (A) and Vc + 3 (B)
groups, the expression level of Dlk1, Rtl1 and Dio3 was significantly lower
in BGHPES-2 and GHPES-3, compared with BGHPES-1, GHPES-1 and
GHPES-2; however, the expression level of these three genes in all five
hpESCs lines was significantly lower than that in HFES-CONT. In Vc + 5 (A)
and Vc + 10 (B) groups, the expression level of Dlk1, Rtl1 and Dio3 in
BGHPES-2 and GHPES-3 was enhanced and comparable with BGHPES-1,
GHPES-1 and GHPES-2; however, the expression level of these three genes
in all five hpESCs lines was still significantly lower than that in HFES-CONT.
Different letters indicate significant differences among data (P <0.05) while
the same letters are used to signify no differences (P >0.05).
Additional file 9: Figure S8. Cluster analysis of paternally expressed
genes in human parthenogenetic embryonic stem cells. (A) Differences in
expression of Dlk1, Rtl1 and Dio3 between human parthenogenetic
embryonic stem cells that form teratoma and those that do not form
teratoma were observed. (B) No regular changes in Dlk1, Rtl1 and Dio3
were evident in human parthenogenetic embryonic stem cells after
ascorbic acid treatment.
Additional file 10: Figure S9. Cluster analysis of maternally expressed
genes in human parthenogenetic embryonic stem cells. No regular
changes in 20 maternally expressed imprinting genes were evident in
human parthenogenetic embryonic stem cells before (A) or after (B)
ascorbic acid treatment.
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